PTC Therapeutics
PTCT
203 hedge funds and large institutions have $3.47B invested in PTC Therapeutics in 2020 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 89 increasing their positions, 57 reducing their positions, and 26 closing their positions.
119% more call options, than puts
Call options by funds: $34.6M | Put options by funds: $15.8M
56% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 57
21% more capital invested
Capital invested by funds: $2.87B → $3.47B (+$597M)
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
0.76% more ownership
Funds ownership: 102.69% → 103.44% (+0.76%)
0% more funds holding
Funds holding: 203 → 203 (0)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$89.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$87.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$39.9M |
| 4 |
BlackRock
New York
|
+$26.6M |
| 5 |
BAMCO Inc
New York
|
+$24.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$70.4M |
| 2 |
O
OrbiMed
New York
|
-$51.2M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$43M |
| 4 |
Renaissance Technologies
New York
|
-$18.4M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$12.5M |
PTCT Hedge Fund Activity: Q2 2020 in Review
203 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2020, worth a combined $3.47B — up 21% from $2.87B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new PTCT positions and 26 closed out — a net gain of 2 holders — while 89 added to existing stakes and 57 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $89.3M. The largest seller was Great Point Partners, cutting an estimated $70.4M.
- 203 institutional investors held PTC Therapeutics (PTCT) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $3.47B of PTC Therapeutics stock for Q2 2020, up 21% quarter-over-quarter.
- 28 funds opened new PTC Therapeutics positions in Q2 2020 and 26 closed out, a net change of +2 holders.
- The largest PTC Therapeutics buyer in Q2 2020 was Fidelity Investments, an estimated $89.3M added.
- The largest PTC Therapeutics seller in Q2 2020 was Great Point Partners, an estimated $70.4M sold.
Based on aggregated 13F filings for Q2 2020.